Christopher I Wright Alkermes Plc. (ALKS) insider trading activity

Christopher I Wright is Director of Alkermes plc.. Currently has a direct ownership of 23,013 shares of ALKS, which is worth approximately $677,042. The most recent transaction as insider was on Jun 08, 2025, when has been sold 793 shares (Ordinary Shares) at a price of $31.71 per share, resulting in proceeds of $25,146. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 23K

59.64% 3M change

135.38% 12M change

Total Value Held $677,042

Christopher I Wright Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 08 2025	SELL Payment of exercise price or tax liability	$25,146 $31.71 p/Share	793 Reduced 3.33%	23,013 Ordinary Shares
Jun 08 2025	BUY Exercise of conversion of derivative security	-	3,301 Added 12.18%	23,806 Ordinary Shares
May 31 2025	SELL Payment of exercise price or tax liability	$58,893 $30.61 p/Share	1,924 Reduced 8.58%	20,505 Ordinary Shares
May 31 2025	BUY Exercise of conversion of derivative security	-	8,013 Added 26.32%	22,429 Ordinary Shares
Jun 29 2024	SELL Payment of exercise price or tax liability	$35,306 $24.1 p/Share	1,465 Reduced 9.22%	14,416 Ordinary Shares
Jun 29 2024	BUY Exercise of conversion of derivative security	-	6,104 Added 27.76%	15,881 Ordinary Shares
Jun 08 2024	SELL Payment of exercise price or tax liability	$18,960 $23.91 p/Share	793 Reduced 7.5%	9,777 Ordinary Shares
Jun 08 2024	BUY Exercise of conversion of derivative security	-	3,301 Added 23.8%	10,570 Ordinary Shares
Jul 07 2023	SELL Payment of exercise price or tax liability	$42,728 $29.88 p/Share	1,430 Reduced 16.44%	7,269 Ordinary Shares
Jul 07 2023	BUY Exercise of conversion of derivative security	-	5,957 Added 40.65%	8,699 Ordinary Shares
Jun 08 2023	SELL Payment of exercise price or tax liability	$27,345 $31.54 p/Share	867 Reduced 24.02%	2,742 Ordinary Shares
Jun 08 2023	BUY Exercise of conversion of derivative security	-	3,609 Added 50.63%	3,519 Ordinary Shares

Also insider at

CYCN

Cyclerion Therapeutics, Inc. Healthcare

Chief Medical Officer

CIW